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Summary
The Food and Drug Administration (FDA) has recently
recommended that the label dose of Gadolinium (Gd)-
based contrast agents (GBCA) not be exceeded. The pri-
mary concern for high dose GBCAs application is
nephrogenic systemic fibrosis (NSF). For the majority of
conventional GBCA, the label dose is 0.1 mmol/kg.
GBCA use for evaluation of myocardial disease is cur-
rently considered off-label use in the United States. Lit-
tle information is present in the literature regarding
optimal GBCA dose for CMR. Therefore, we evaluated
the current status of GBCA use for CMR of the myocar-
dium as presented in the peer-reviewed literature,
emphasizing trends before and after nephrogenic fibrosis
guidelines were issued in 2008. This meta-analysis
showed that the median GBCA dose for English peer
reviewed publications on CMR (19,934 patients) was 0.2
mmol/kg. Further, no change in mean or median gadoli-
nium dose was present before, versus after the FDA
issued GBCA black box warnings (p>0.05). This appears
surprising, given the amount of attention and many
publications regarding NSF. It remains to be seen if
future CMR studies will incorporate and report lower
gadolinium doses. Clinical trials should be supported to
determine the appropriate doses of gadolinium enhance-
ment of the myocardium.
Background
Myocardial delayed enhancement MRI was originally
validated using higher than label-recommended doses of
gadolinium chelate. The objective of this study was to
evaluate available evidence for various gadolinium dos-
ing regimens used for cardiac MRI. The relationship of
gadolinium dose warnings (due to nephrogenic systemic
fibrosis) announced in 2008 to gadolinium dosing regi-
mens was also examined.
Methods
We conducted a meta-analysis of peer reviewed publica-
tions from January, 2004 to December, 2010. Major sub-
ject search headings (MeSh) terms from the National
Library of Medicine’s PubMed were: contrast media,
gadolinium, heart, magnetic resonance imaging; searches
were limited to human studies with abstracts published
in English. Case reports, review articles, editorials, MRA
related papers and all reports that did not indicate gado-
linium type or weight-based dose were excluded. For all
included references, full text was available to determine
the total administered gadolinium dose on a per kg
basis. Average and median dose values were weighted by
the number of subjects in each study.
Results
399 publications were identified in PubMed; 233 studies
matched the inclusion criteria, encompassing 19,934
patients with mean age 54.2±11.4 (range 9.3 to 76
years). 34 trials were related to perfusion testing and
199 to myocardial delayed enhancement. In 2004, the
weighted-median and weighted-mean contrast dose
were 0.15 and 0.16±0.06 mmol/kg, respectively. Median
contrast doses for 2005-2010 were: 0.2 mmol/kg for all
years, respectively. Mean contrast doses for the years
2005-2010 were: 0.19±0.03, 0.18±0.04, 0.18±0.10, 0.18
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for trend, NS). Gadopentetate dimeglumine was the
most frequent gadolinium type [114 (48.9%) studies]. No
change in mean gadolinium dose was present before,
versus after the FDA black box warning (p>0.05). Three
multi-center dose ranging trials have been published for
cardiac MRI applications.
Conclusions
Cardiac MRI studies in the peer-reviewed published lit-
erature routinely use higher gadolinium doses than FDA
indicated dose. Clinical trials should be supported to
determine the appropriate doses of gadolinium enhance-
ment of the myocardium.
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Table 1 Characteristics of publications included in the meta-analysis
Year Studies Participants Age (years) Perfusion studies LGE studies Median GBCA dose (mmol/Kg)* Mean GBCA dose (mmol/Kg)*
2004 22 (9.5) 697 (3.5) 56.1±8.7 6 (17.6) 16 (8.1) 0.15 0.16±0.06
2005 19 (8.2) 2,123 (10.7) 54.4±8.4 2 (5.9) 17 (8.6) 0.2 0.19±0.03
2006 26 (11.1) 4,366 (22.0) 54.9±11.3 5 (14.8) 21 (10.5) 0.2 0.18±0.04
2007 31 (13.3) 1,123 (5.6) 46.1±16.9 3 (8.9) 28 (14.1) 0.2 0.18±0.04
2008 40 (17.1) 2,264 (11.3) 55±8.9 7 (20.5) 33 (16.5) 0.2 0.18±0.03
2009 45 (19.3) 3,965 (19.9) 56.2±10.3 5 (14.7) 40 (20.1) 0.2 0.18±0.04
2010 50 (21.5) 5,396 (27.0) 55±11.3 6 (17.6) 44 (22.1) 0.2 0.18±0.04
Total 233 (100) 19,934 (100) 54.2±11.4 34 (100) 199 (100) 0.2 0.18±0.04
Note: Median, mean and standard deviations or number and percentages as appropriate. LGE, late gadolinium enhancement. Studies that had both LGE and
perfusion results were categorized as LGE . For these studies, total gadolinium dose is shown.
Figure 1 (A) Weighted mean contrast dose (mmol/Kg) from 2004
to 2010. (B) No change in mean gadolinium contrast dose before
versus after FDA black box warning. Dashed horizontal lines
represents minimum contrast dose and horizontal lines represents
maximum contrast dose.
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